|
業務類別
|
-- |
|
業務概覽
|
CanSino Biologics Inc is engaged in the research and development, manufacturing, and commercialization of vaccine products for human use. The company has a broad portfolio of vaccines and vaccine candidates for several disease areas. Its commercial-stage products are Menhycia and Menphecia, iPneucia, Convidecia and Convidecia Air, and XBB.1.5 Variant, and Ad5-EBOV. The company's clinical-stage products include Tetanus Vaccine, DTcP Infant, Tdcp Adolescent and Adult, Recombinant Poliomyelitis Vaccine, PBPV, and Recombinant Zoster Vaccine, among others. Additionally, it has various vaccine candidates in pre-clinical programs, targeting diseases such as influenza, meningitis, pneumonia, and others. Geographically, the company generates maximum revenue from the People's Republic of China. |
| 公司地址
| 185 South Avenue, 401-420, 4th Floor, Biomedical Park, TEDA West District, Tianjin, CHN |
| 電話號碼
| +86 4009222099 |
| 傳真號碼
| +86 2258213626 |
| 公司網頁
| https://www.cansinotech.com |
| 員工數量
| 1134 |
| Dr. Yu Xuefeng |
Chairman of the Board, Chief Executive Officer and General Manager |
-- |
22/04/2026 |
| Dr. Bai Chao Shou |
Director, Chief Operating Officer and Deputy General Manager |
-- |
22/04/2026 |
| Ms. Jing Wang |
Director, Chief Commercial Officer and Deputy General Manager |
-- |
22/04/2026 |
|
|
| Mr. Chi Shing Li |
Director |
22/04/2026 |
| Ms. Xuefeng Ji |
Independent Director |
22/04/2026 |
| Dr. Yu Xuefeng |
Chairman of the Board, Chief Executive Officer and General Manager |
22/04/2026 |
| Dr. Bai Chao Shou |
Director, Chief Operating Officer and Deputy General Manager |
22/04/2026 |
| Mr. Yiu Leung Andy Cheung |
Independent Director |
22/04/2026 |
| Ms. Jing Wang |
Director, Chief Commercial Officer and Deputy General Manager |
22/04/2026 |
| Mr. Man Cho |
Independent Director |
22/04/2026 |
|
|
|
|
